Laboratorio Farmaceutico Erfo SpA is an Italy-based pharmaceutical company primarily engaged in the nutraceutical sector. The Company specializes in the production of nutritional supplements, that thanks to research and development carried out internally and in collaboration with the University Campus Bio-Medico of Rome and the University of Messina provides products with a scientific value in different therapeutic areas. The Company operates globally.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
11/09/26	€1.085	-0.46%	12,000
10/09/26	€1.090	-0.91%	15,000
09/09/26	€1.100	-1.35%	9,000
08/09/26	€1.115	-0.45%	14,000
07/09/26	€1.120	+0.90%	3,000

Real-time Borsa Italiana

More quotes

Annual profits - Rate of surprise

Company calendar

Market Closed - Borsa Italiana 23:45:00 11/09/2026 HKT			5-day change	1st Jan Change
1.085 ^EUR	-0.46%		-2.25%	-26.19%

08-31	Milan in the pink at the open, oil stocks lead the MIB	AN
08-31	Futures weak; Brent higher after US-Iran attacks	AN

Market Cap	9.29M 10.78M 8.79M 7.97M 14.95M 1.03B 15.03M 104M 40.16M 524M 40.48M 39.59M 1.66B	P/E 2024	30.8x	P/E 2025	17x
Enterprise Value	9.58M 11.12M 9.07M 8.22M 15.43M 1.06B 15.51M 108M 41.44M 541M 41.77M 40.85M 1.71B	EV / Sales 2024	1.79x	EV / Sales 2025	1.32x
Free-Float	33.31%	Yield 2024 *	-	Yield 2025	-

Markets		Quality
Borsa Italiana	ERFO	Real-time
Deutsche Boerse AG	RK7	Delayed

08-31	Milan in the pink at the open, oil stocks lead the MIB	AN
08-31	Futures weak; Brent higher after US-Iran attacks	AN
08-29	Buying across Europe, Lottomatica goes all-in on the MIB	AN
08-28	Europe pushes higher at the halfway mark, MIB at 52,700	AN
08-28	Laboratorio Farmaceutico Erfo closes half-year with revenue up 2%	AN
08-27	Milan opens lower; STM jumps after Nvidia earnings	AN
08-26	Piazza Affari ends higher, Buzzi leads the MIB	AN
07-07	Laboratorio Erfo continues buyback, acquires 15,000 treasury shares	AN
06-29	Laboratorio Farmaceutico Erfo buys back 14,000 treasury shares	AN
06-22	Erfo Keeps Buying Back Stock, Repurchases 28,000 Shares	AN
06-20	Laboratorio Farmaceutico Erfo S.p.A.'s Equity Buyback announced on December 18, 2024, has expired.	CI
06-15	Laboratorio Farmaceutico Erfo acquires 15,000 treasury shares	AN
06-04	Equities trend higher; banks lead gains on the MIB	AN

Laboratorio Farmaceutico Erfo S.p.A. Stock

Stocks

ERFO

IT0005497885

Pharmaceuticals

Valuation : Laboratorio Farmaceutico Erfo S.p.A.

Chart: Laboratorio Farmaceutico Erfo S.p.A.

Latest news : Laboratorio Farmaceutico Erfo S.p.A.

Press Releases : Laboratorio Farmaceutico Erfo S.p.A.

News in other languages : Laboratorio Farmaceutico Erfo S.p.A.

Quotes and Performance

Price Extremes

Managers and Directors : Laboratorio Farmaceutico Erfo S.p.A.

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

04-10	Laboratorio Farmaceutico Erfo S p A : Investor Presentation Erfo SpA FY2025 (ENG)	PU
21/10/25	Laboratorio Farmaceutico Erfo S p A : 2025 10 20-ERFO-NextGEMS	PU
29/08/25	Laboratorio Farmaceutico Erfo S p A : 2025 08 28 ERFO - Press release KPI 1H 2025	PU
04/06/25	Laboratorio Farmaceutico Erfo S p A : KT Erfo 1Q25 Final	PU
19/05/25	Laboratorio Farmaceutico Erfo S p A : KT Erfo FY24 Final	PU

08-31	Milano maglia rosa in avvio; sul MIB guidano le oil
08-31	Futures deboli; Brent su dopo attacchi USA-Iran
08-29	Buy in tutta Europa, Lottomatica fa all-in sul MIB
08-28	Europee di slancio al giro di boa; MIB a 52.700
08-28	Laboratorio Farmaceutico Erfo archivia semestre con ricavi su del 2%

1 day	-0.46%
1 week	-2.25%
Current month	-5.65%
1 month	-2.25%
3 months	-0.46%
6 months	-13.55%
Current year	-26.19%

1 week	1.08	1.12
1 month	1.08	1.18
Current year	1.01	1.6
1 year	1.01	1.8
3 years	0.88	1.8
5 years	0.88	3.3
10 years	0.88	3.3

Manager	Title	Age	Since
Alessandro Cutè CEO	Chief Executive Officer	56	01/01/2013
Daniele Travisano DFI	Director of Finance/CFO	-	-

Director	Title	Age	Since
Alessandro Cutè CHM	Chairman	56	01/01/2013
Flavio Corpina BRD	Director/Board Member	47	01/01/2017
Fabio Giuffre BRD	Director/Board Member	45	-

Date	Insider	Type	Main position	Quantity	% Market Cap.
16/12/25	Alessandro Cutè	Sell	Chief Executive Officer	968,000	10.7556%
16/12/25	Alessandro Cutè	Sell	Chief Executive Officer	322,000	3.5778%
29/6/22	Alessandro Cutè	Others	Chief Executive Officer	300,000	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LABORATORIO FARMACEUTICO ERFO S.P.A.	-0.46%	-2.25%	-22.22%	-11.79%	10.8M
ELI LILLY AND COMPANY	+0.09%	-2.14%	+48.72%	+88.86%	1,001B
JOHNSON & JOHNSON	-0.10%	-3.41%	+48.93%	+63.43%	642B
ABBVIE INC.	+1.03%	+0.34%	+16.85%	+72.66%	451B
ROCHE HOLDING AG	-0.38%	-3.59%	+28.24%	+35.57%	340B
NOVARTIS AG	-0.09%	-13.54%	+10.08%	+26.87%	263B
ASTRAZENECA PLC	-0.43%	-2.48%	-2.07%	+11.48%	247B
AMGEN INC.	-0.66%	-13.12%	+34.36%	+45.15%	207B
NOVO NORDISK A/S	-3.44%	-7.51%	-20.08%	-59.58%	197B
GILEAD SCIENCES, INC.	-0.50%	-4.61%	+22.20%	+86.95%	180B
Average	-0.46%	-5.15%	+16.50%	+35.96%	352.63B
Weighted average by Cap.	-0.17%	-4.65%	+30.24%	+56.04%

	2024	2025
Net sales	6.03M 7M 5.71M 5.18M 9.71M 669M 9.76M 67.84M 26.09M 340M 26.29M 25.72M 1.08B	9.73M 11.29M 9.21M 8.35M 15.67M 1.08B 15.75M 109M 42.08M 549M 42.42M 41.49M 1.73B
Net income	353K 409K 334K 303K 568K 39.12M 571K 3.97M 1.53M 19.9M 1.54M 1.5M 62.89M	737K 855K 698K 632K 1.19M 81.72M 1.19M 8.29M 3.19M 41.57M 3.21M 3.14M 131M
Net Debt	5.77K 6.69K 5.46K 4.95K 9.29K 639K 9.33K 64.85K 24.94K 325K 25.14K 24.59K 1.03M	295K 343K 280K 254K 476K 32.76M 478K 3.32M 1.28M 16.67M 1.29M 1.26M 52.66M